Betaxolol is a cardioselective beta-1 adrenergic receptor antagonist belonging to the class of beta-blockers. It is primarily used in the management of hypertension and, in its ophthalmic formulation, for the treatment of chronic open-angle glaucoma and ocular hypertension. This report provides a detailed overview of betaxolol's pharmacological properties, therapeutic indications, adverse effects, and clinical considerations.

Pharmacology

Betaxolol is a lipophilic, beta-1 selective blocker with minimal intrinsic sympathomimetic activity (ISA) and no significant membrane-stabilizing activity. Its selectivity for beta-1 receptors predominates at lower doses, but at higher concentrations, beta-2 blockade may occur. Betaxolol is approximately 50% protein-bound and has a relatively long elimination half-life of 16 to 22 hours, allowing once-daily dosing in hypertension. It is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6, and excreted predominantly in the urine as metabolites. The drug's oral bioavailability is about 90%, and peak plasma concentrations occur within 2 to 6 hours.

The mechanism of action involves competitive blockade of beta-1 receptors in the heart, leading to decreased heart rate, myocardial contractility, and cardiac output. This results in reduced systolic and diastolic blood pressure. Renin release from the kidneys is also inhibited, further contributing to antihypertensive effects. In the eye, pharmacie-Ruthen-pharma.com, betaxolol reduces intraocular pressure (IOP) by decreasing the production of aqueous humor, likely through beta-2 receptor blockade in the ciliary epithelium, despite its cardioselectivity.

Clinical Indications

1. Hypertension: Betaxolol is indicated for the management of essential hypertension, either alone or in combination with other antihypertensive agents. Its long half-life permits once-daily administration, improving adherence. Clinical trials have demonstrated efficacy in reducing blood pressure comparable to other beta-blockers like atenolol. It is particularly beneficial in patients with concomitant conditions such as stable angina or tachyarrhythmias.
2. 
   
3. 
   
4. Glaucoma and Ocular Hypertension: The ophthalmic formulation (0.25% or 0.5% solution) is widely used to lower IOP in patients with chronic open-angle glaucoma and ocular hypertension. Betaxolol's selectivity reduces the risk of pulmonary adverse effects compared to non-selective beta-blockers like timolol, making it a safer option for patients with reactive airway disease. It is effective as monotherapy or adjunctive therapy with other glaucoma medications such as prostaglandin analogs or carbonic anhydrase inhibitors.
5. 
   
6. 
   

Systemic use of betaxolol may cause typical beta-blocker side effects, though its cardioselectivity reduces the incidence of bronchospasm and peripheral vasoconstriction. Common adverse effects include bradycardia, hypotension, fatigue, dizziness, cold extremities, and gastrointestinal disturbances (nausea, diarrhea). Less common but serious effects include heart failure exacerbation, heart block, and depression. Because of its lipophilicity, central nervous system side effects such as insomnia, nightmares, and fatigue may occur, though less frequently than with propranolol.

Ophthalmic betaxolol can cause local irritation, blurred vision, transient stinging, and conjunctival hyperemia. Systemic absorption is minimal but may still produce beta-blockade effects in susceptible individuals, particularly those with preexisting bradycardia or asthma. However, the incidence of pulmonary effects is significantly lower than with non-selective agents. Rarely, allergic reactions or corneal anesthesia have been reported.

Contraindications and Precautions

Betaxolol is contraindicated in patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, overt heart failure, and severe peripheral arterial disease. Caution is advised in patients with reactive airway disease (asthma or COPD), diabetes mellitus (beta-blockers may mask hypoglycemic symptoms), hyperthyroidism, and renal or hepatic impairment. Abrupt discontinuation should be avoided due to the risk of rebound hypertension, exacerbation of angina, or myocardial infarction.

Drug interactions include potentiation of bradycardia with other negative chronotropic agents (e.g., verapamil, diltiazem, digoxin), increased hypotensive effect with other antihypertensives, and possible altered metabolism with CYP2D6 inhibitors or inducers. In glaucoma patients, concurrent use of oral beta-blockers may require dose adjustment due to additive IOP-lowering effects.

Conclusion

Betaxolol is a well-established beta-1 selective blocker with distinct advantages in hypertensive patients with respiratory comorbidities and in ophthalmic practice for glaucoma management. Its pharmacokinetic profile allows convenient once-daily dosing, and its safety profile is favorable when used appropriately. Ongoing monitoring of heart rate, blood pressure, respiratory status, and ocular response is essential to optimize therapeutic outcomes and minimize risks. As with all beta-blockers, individualized therapy and patient education are paramount.